One little pearl from the Allergan investor presentation is that the company is expecting Rhofade to be approved by the FDA in early 2017.
About: Allergan plc (AGN)
William J. Meury – Chief Commercial Officer
Finally, early commercialization activities are underway to support our 2017 launches, XEN, True Tear, formerly known as Oculeve, and oxymetazoline for rosacea, which we’re now calling Rhofade.
Following FDA acceptance of our NDA for oxymetazoline, Rhofade, for the topical treatment of rosacea in adults, we anticipate approval early next year.